vTv Therapeutics (VTVT) Long-Term Debt Repayments (2015 - 2016)

vTv Therapeutics (VTVT) reported Long-Term Debt Repayments of $4000.0 for Q4 2016, down 20.0% sequentially from $5000.0 in Q3 2016.

vTv Therapeutics (VTVT) Long-Term Debt Repayments (2015 - 2016) Analysis & Trends

vTv Therapeutics (VTVT) has 2 years of Long-Term Debt Repayments data on file, last reported at $4000.0 in Q4 2016.

For the quarter ending Q4 2016, Long-Term Debt Repayments changed N/A year-over-year to $4000.0; the trailing twelve-month figure through Dec 2016 stood at $22000.0 (changed N/A YoY), and the FY2016 full-year result was $33000.0, down 62.92% from the prior year.
Long-Term Debt Repayments fell to $4000.0 in Q4 2016, from $5000.0 in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $13000.0 in Q3 2015 to a low of $4000.0 in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	7.64 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	vTv Therapeutics	19.21 Mn	19.21 Mn	-	-

Download Data